CNBC reports that Eli Lilly and Novo Nordisk are both accelerating their bets on the amylin pathway as a core next-generation mechanism in obesity drug development. The amylin route is widely seen as a key target that may deliver fresh breakthroughs in weight-loss magnitude, tolerability, and broader metabolic regulation after the GLP-1 class of drugs such as semaglutide and Zepbound.
Latest clinical data show that Lilly’s experimental amylin-based combination regimen outperformed its flagship product Zepbound on weight loss, drawing heavy industry attention to the future commercial outlook of amylin therapies. Novo Nordisk is also advancing multiple amylin candidates in its research pipeline to consolidate its long-term leadership in obesity and metabolic disease. This new round of R&D competition is expected to push the obesity drug market into a “mechanism diversification” stage and to deliver new therapeutic options to patient populations.
Editor: GoodInfo Global News Team